{"entity":{"type":"insider","cik":"0001796820","url":"/insider/0001796820","json_url":"/insider/0001796820.json","name":"NEA Partners 17, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":7,"n_filings":7,"first":"2021-06-30","last":"2026-03-12","span_basis":"filed_date"},"name_variants":[{"name":"NEA Partners 17, L.P.","source":"filing","n_filings":7,"first_seen":"2021-06-30","last_seen":"2026-03-12"}],"transactions":[{"id":6001602,"accession":"0001193125-26-104719","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-104719","line_url":"/filing/0001193125-26-104719#line-1","is_derivative":false,"issuer_cik":"0001703647","issuer_name":"Korro Bio, Inc.","issuer_ticker":"KRRO","issuer_name_source":null,"issuer_url":"/issuer/0001703647","owner_cik":null,"owner_name":"NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":207100.0,"shares_display":"207,100","price_per_share":11.11,"price_display":"11.11","price_state":"stated","total_value":2300881.0,"total_display":"2,300,881.00","shares_owned_after":1297893.0,"shares_owned_after_display":"1,297,893","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-10","filed_date":"2026-03-12","scope":"insider"},{"id":6087213,"accession":"0001193125-26-046671","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193125-26-046671","line_url":"/filing/0001193125-26-046671#line-5","is_derivative":false,"issuer_cik":"0001768564","issuer_name":"SpyGlass Pharma, Inc.","issuer_ticker":"SGP","issuer_name_source":null,"issuer_url":"/issuer/0001768564","owner_cik":null,"owner_name":"NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":937500.0,"shares_display":"937,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":15000000.0,"total_display":"15,000,000.00","shares_owned_after":6035038.0,"shares_owned_after_display":"6,035,038","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-09","filed_date":"2026-02-11","scope":"insider"},{"id":4372218,"accession":"0001193125-25-232131","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-232131","line_url":"/filing/0001193125-25-232131#line-4","is_derivative":false,"issuer_cik":"0001671284","issuer_name":"NeueHealth, Inc.","issuer_ticker":"NEUE","issuer_name_source":null,"issuer_url":"/issuer/0001671284","owner_cik":null,"owner_name":"NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P.","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":280.0,"shares_display":"280","price_per_share":6.75,"price_display":"6.75","price_state":"stated","total_value":1890.0,"total_display":"1,890.00","shares_owned_after":488702.0,"shares_owned_after_display":"488,702","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-02","filed_date":"2025-10-06","scope":"insider"},{"id":2951701,"accession":"0000950170-24-107537","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-107537","line_url":"/filing/0000950170-24-107537#line-3","is_derivative":false,"issuer_cik":"0001768564","issuer_name":"MBX Biosciences, Inc.","issuer_ticker":"MBX","issuer_name_source":null,"issuer_url":"/issuer/0001768564","owner_cik":null,"owner_name":"NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":8000000.0,"total_display":"8,000,000.00","shares_owned_after":3614486.0,"shares_owned_after_display":"3,614,486","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-17","scope":"insider"},{"id":2176744,"accession":"0000950170-24-047686","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-047686","line_url":"/filing/0000950170-24-047686#line-1","is_derivative":false,"issuer_cik":"0001703647","issuer_name":"Korro Bio, Inc.","issuer_ticker":"KRRO","issuer_name_source":null,"issuer_url":"/issuer/0001703647","owner_cik":null,"owner_name":"NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17857.0,"shares_display":"17,857","price_per_share":56.0,"price_display":"56.00","price_state":"stated","total_value":999992.0,"total_display":"999,992.00","shares_owned_after":1090793.0,"shares_owned_after_display":"1,090,793","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-22","filed_date":"2024-04-24","scope":"insider"},{"id":8078157,"accession":"0001209191-23-042795","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-042795","line_url":"/filing/0001209191-23-042795#line-1","is_derivative":false,"issuer_cik":"0001160308","issuer_name":"Savara Inc","issuer_ticker":"SVRA","issuer_name_source":null,"issuer_url":"/issuer/0001160308","owner_cik":null,"owner_name":"New Enterprise Associates 17, L.P.; Growth Equity Opportunities 17, LLC; NEA Partners 17, L.P.; NEA 17 GP, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":333333.0,"shares_display":"333,333","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":999999.0,"total_display":"999,999.00","shares_owned_after":24471264.0,"shares_owned_after_display":"24,471,264","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-17","filed_date":"2023-07-19","scope":"insider"},{"id":5293105,"accession":"0001209191-21-044033","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-044033","line_url":"/filing/0001209191-21-044033#line-4","is_derivative":false,"issuer_cik":"0001768564","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001768564","owner_cik":null,"owner_name":"NEA Partners 17, L.P.; NEA 17 GP, LLC; New Enterprise Associates 17, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1050000.0,"shares_display":"1,050,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":19950000.0,"total_display":"19,950,000.00","shares_owned_after":7692298.0,"shares_owned_after_display":"7,692,298","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-28","filed_date":"2021-06-30","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001703647","name":"Korro Bio, Inc.","url":"/issuer/0001703647","role":"Ten percent owner","n_filings":2,"first_seen":"2024-04-24","last_seen":"2026-03-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001778922","name":"SpyGlass Pharma, Inc.","url":"/issuer/0001778922","role":"Ten percent owner","n_filings":1,"first_seen":"2026-02-11","last_seen":"2026-02-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001671284","name":"NeueHealth, Inc.","url":"/issuer/0001671284","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2025-10-06","last_seen":"2025-10-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001776111","name":"MBX Biosciences, Inc.","url":"/issuer/0001776111","role":"Ten percent owner","n_filings":1,"first_seen":"2024-09-17","last_seen":"2024-09-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001160308","name":"Savara Inc","url":"/issuer/0001160308","role":"Ten percent owner","n_filings":1,"first_seen":"2023-07-19","last_seen":"2023-07-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001826457","name":"Monte Rosa Therapeutics, Inc.","url":"/issuer/0001826457","role":"Ten percent owner","n_filings":1,"first_seen":"2021-06-30","last_seen":"2021-06-30"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001796820","retrieved_at":"2026-08-21T20:19:07+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}